Acasti Pharma Discusses Positive Clinical Study Results for GTX-101 and GTX-102 and Upcoming Phase 3 Study for GTX-104 with The Stock Day Podcast

from Stock Day Media · host Stock Day Media

The Stock Day Podcast welcomed Acasti Pharma, Inc. (Nasdaq:ACST), a late-stage specialty pharma company with drug delivery technologies and drug candidates addressing rare and orphan diseases. CEO of the Company, Jan D’Alvise, joined Stock Day host Everett Jolly. Advertising Inquiries: https://redcircle.com/brandsPrivacy & Opt-Out: https://redcircle.com/privacy

Episode metadata supplied by the publisher feed · Published Jan 17, 2023

Embed this episode

Attribution link and audio player

Ready to play

Acasti Pharma Discusses Positive Clinical Study Results for GTX-101 and GTX-102 and Upcoming Phase 3 Study for GTX-104 with The Stock Day Podcast

0:00 15:58

1×

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Share this episode

Similar Episodes

No similar episodes found.

Similar Podcasts

Wild WinsDay Wild WinsDay Pump the hump with WILD WINSday 🐪💪: Your 3-minute weekly video boost for leadership, sales, marketing, and business breakthroughs to WIN the day!

Frequently Asked Questions

How long is this episode of Stock Day Media?

This episode is 15 minutes long.

When was this Stock Day Media episode published?

This episode was published on January 17, 2023.

Can I download this Stock Day Media episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.

URL copied to clipboard!